| 1. |
|
|
| 2. |
- Adare, A., et al.
(författare)
-
Systematic study of azimuthal anisotropy in Cu plus Cu and Au plus Au collisions at root s(NN)=62.4 and 200 GeV
- 2015
-
Ingår i: Physical Review C (Nuclear Physics). - 0556-2813. ; 92:3
-
Tidskriftsartikel (refereegranskat)abstract
- We have studied the dependence of azimuthal anisotropy nu(2) for inclusive and identified charged hadrons in Au + Au and Cu + Cu collisions on collision energy, species, and centrality. The values of nu(2) as a function of transverse momentum pT and centrality in Au + Au collisions at root s(NN) = 200 and 62.4 GeV are the same within uncertainties. However, in Cu + Cu collisions we observe a decrease in nu(2) values as the collision energy is reduced from 200 to 62.4 GeV. The decrease is larger in the more peripheral collisions. By examining both Au + Au and Cu + Cu collisions we find that nu(2) depends both on eccentricity and the number of participants, N-part. We observe that nu(2) divided by eccentricity (epsilon) monotonically increases with N-part and scales as N-part(1/3). The Cu + Cu data at 62.4 GeV falls below the other scaled nu(2) data. For identified hadrons, nu(2) divided by the number of constituent quarks n(q) is independent of hadron species as a function of transverse kinetic energy K E-T = m(T) - m between 0.1 < K E-T / n(q) < 1 GeV. Combining all of the above scaling and normalizations, we observe a near-universal scaling, with the exception of the Cu + Cu data at 62.4 GeV, of nu(2)/(nq center dot e center dot N-part(1/3)) vs K E-T / n(q) for all measured particles.
|
|
| 3. |
- Brunner, Fabian J., et al.
(författare)
-
Application of non-HDL cholesterol for population-based cardiovascular risk stratification : results from the Multinational Cardiovascular Risk Consortium
- 2019
-
Ingår i: The Lancet. - : Elsevier. - 0140-6736 .- 1474-547X. ; 394:10215, s. 2173-2183
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment.Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol.Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7–59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0–20·1), 54 542 cardiovascular endpoints occurred. Incidence curve analyses showed progressively higher 30-year cardiovascular disease event-rates for increasing non-HDL cholesterol categories (from 7·7% for non-HDL cholesterol <2·6 mmol/L to 33·7% for ≥5·7 mmol/L in women and from 12·8% to 43·6% in men; p<0·0001). Multivariable adjusted Cox models with non-HDL cholesterol lower than 2·6 mmol/L as reference showed an increase in the association between non-HDL cholesterol concentration and cardiovascular disease for both sexes (from hazard ratio 1·1, 95% CI 1·0–1·3 for non-HDL cholesterol 2·6 to <3·7 mmol/L to 1·9, 1·6–2·2 for ≥5·7 mmol/L in women and from 1·1, 1·0–1·3 to 2·3, 2·0–2·5 in men). The derived tool allowed the estimation of cardiovascular disease event probabilities specific for non-HDL cholesterol with high comparability between the derivation and validation cohorts as reflected by smooth calibration curves analyses and a root mean square error lower than 1% for the estimated probabilities of cardiovascular disease. A 50% reduction of non-HDL cholesterol concentrations was associated with reduced risk of a cardiovascular disease event by the age of 75 years, and this risk reduction was greater the earlier cholesterol concentrations were reduced.Interpretation: Non-HDL cholesterol concentrations in blood are strongly associated with long-term risk of atherosclerotic cardiovascular disease. We provide a simple tool for individual long-term risk assessment and the potential benefit of early lipid-lowering intervention. These data could be useful for physician–patient communication about primary prevention strategies.
|
|
| 4. |
- Papaevangelou, T., et al.
(författare)
-
ESS nBLM : Beam loss monitors based on fast neutron detection
- 2018
-
Ingår i: HB2018 - Proceedings of the 61st ICFA Advanced Beam Dynamics Workshop on High-Intensity and High-Brightness Hadron Beams. - 9783954502028 ; , s. 404-409
-
Konferensbidrag (refereegranskat)abstract
- A new type of Beam Loss Monitor (BLM) system is being developed for use in the European Spallation Source (ESS) linac, primarily aiming to cover the low energy part (proton energies between 3-100 MeV). In this region of the linac, typical BLM detectors based on charged particle detection (i.e. Ionization Chambers) are not appropriate because the expected particle fields will be dominated by neutrons and photons. Another issue is the photon background due to the RF cavities, which is mainly due to field emission from the electrons from the cavity walls, resulting in bremsstrahlung photons. The idea for the ESS neutron sensitive BLM system (ESS nBLM) is to use Micromegas detectors specially designed to be sensitive to fast neutrons and insensitive to low energy photons (X and gammas). In addition, the detectors must be insensitive to thermal neutrons, because those neutrons may not be directly correlated to beam losses. The appropriate configuration of the Micromegas operating conditions will allow excellent timing, intrinsic photon background suppression and individual neutron counting, extending thus the dynamic range to very low particle fluxes.
|
|
| 5. |
- Goyal, S. D., et al.
(författare)
-
Allogeneic hematopoietic cell transplant for AML : no impact of pre-transplant extramedullary disease on outcome
- 2015
-
Ingår i: Bone Marrow Transplantation. - : Springer Science and Business Media LLC. - 0268-3369 .- 1476-5365. ; 50:8, s. 1057-1062
-
Tidskriftsartikel (refereegranskat)abstract
- The impact of extramedullary disease (EMD) in AML on the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) is unknown. Using data from the Center for International Blood and Marrow Transplant Research, we compared the outcomes of patients who had EMD of AML at any time before transplant, with a cohort of AML patients without EMD. We reviewed data from 9797 AML patients including 814 with EMD from 310 reporting centers and 44 different countries, who underwent alloHCT between and 1995 and 2010. The primary outcome was overall survival (OS) after alloHCT. Secondary outcomes included leukemia-free survival (LFS), relapse rate and treatment-related mortality (TRM). In a multivariate analysis, the presence of EMD did not affect either OS (hazard ratio 1.00, 95% confidence interval (Cl) 0.91-1.09), LFS (0.98, 0.89-1.09), TRM (relative risk 0.92, 95% CI 0.80-1.16, P=0.23) or relapse (relative risk= 1.03, 95% CI, 0.92-1.16; P=0.62). Furthermore, the outcome of patients with EMD was not influenced by the location, timing of EMD, or intensity of conditioning regimen. The presence of EMD in AML does not affect transplant outcomes and should not be viewed as an independent adverse prognostic feature.
|
|
| 6. |
- Shea, T. J., et al.
(författare)
-
Overview and status of diagnostics for the ESS project
- 2018
-
Ingår i: Proceedings of the 6th International Beam Instrumentation Conference, IBIC 2017. - 9783954501922 ; , s. 8-15
-
Konferensbidrag (refereegranskat)abstract
- The European Spallation Source, now under construction in Lund, Sweden, aims to be the world's most powerful pulsed neutron scattering facility. Driving the neutron source is a 5 MW superconducting proton linear accelerator operating at 4 percent beam duty factor and 14 Hz repetition rate. Nineteen partner institutions from across Europe are working with the Accelerator Division in Lund to design and construct the accelerator. The suite of accelerator instrumentation consists of over 20 unique system types developed by over 20 partners and collaborators. Although the organizational complexity presents challenges, it also provides the vast capabilities required to achieve the technical goals. At this time, the beam instrumentation team is in transition, completing the design phase while scaling up to the deployment phase. Commissioning of the ion source has commenced in Catania, preparations for installation on the Lund site are ramping up, and basic R&D on target instrumentation continues. Beam commissioning results from the systems immediately following the ion source will be presented, along with technical highlights and status of the many remaining instrumentation systems.
|
|
| 7. |
- Tuske, O., et al.
(författare)
-
ESS emittance measurements at INFN Catania
- 2017
-
Ingår i: IPAC 2017 - Proceedings of the 8th International Particle Accelerator Conference. - 9783954501823 ; , s. 123-125
-
Konferensbidrag (refereegranskat)abstract
- Beam characteristics at low energy are an absolute necessity for an acceptable injection in the next stage of a linear accelerator, and are also necessary to reduce beam loss and radiation inside the machine. CEA is taking part of ESS linac construction, by designing Emittance Measurement Units (EMU) for the Low Energy Beam Transport (LEBT). The EMU are designed to qualify the proton beam produced by the INFN Catania ion source. The design corresponds to an Allison scanner, using entrance and exit slits, electrostatic plates and a faraday cup. The beam-stopper protects the device and can be removable to fit to beam power. It has been manufactured by the CEA/LITEN with copper tungsten HIP technique. This article report the first measurements on the ESS injector in CATANIA in one dimension.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Betsou, F, et al.
(författare)
-
Standard PREanalytical Code Version 3.0
- 2018
-
Ingår i: Biopreservation and biobanking. - : Mary Ann Liebert Inc. - 1947-5543 .- 1947-5535. ; 16:1, s. 9-12
-
Tidskriftsartikel (refereegranskat)
|
|
